Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test

@article{Michael2011DocetaxelPA,
  title={Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test},
  author={Michael Michael and Carey Cullinane and A. Hatzimihalis and Cecilia M. O’Kane and Alvin Milner and Rhian Booth and Svenja Schlicht and Stephen J. Clarke and Peter Francis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2011},
  volume={69},
  pages={125-135}
}
Docetaxel has marked inter-patient PK variability, and metabolic phenotypic probes may enable individualised dosing. This is the first report directly comparing the erythromycin breath test (EBT) (a CYP3A4 probe) with the antipyrine clearance test (ACT), (a general CYP-P450/predominant CYP3A4 probe) for the correlation with docetaxel PK and toxicity. Patients pretherapy underwent: (A) EBT: IV C14[N-methyl]-erythromycin was administered and breath samples analysed for 14CO2, derived parameters… CONTINUE READING
7 Citations
46 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…